Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391673 | 0.87 | CYP1A2 (0.45) | ATMTDP1LMNARECQLALDH1A1 | |
| SCHEMBL1226349 | 0.86 | SMN1; SMN2 (0.44) | ATMTDP1LMNAALDH1A1HIF1A | |
| SCHEMBL30365116 | 0.86 | SMN1; SMN2 (0.44) | ATMTDP1LMNAALDH1A1HIF1A | |
| SCHEMBL3515877 | 0.86 | LMNA (0.41) | ATMTDP1LMNARECQLALDH1A1 | |
| SCHEMBL297502 | 0.82 | SMN1; SMN2 (0.43) | TDP1LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL3002755 | 0.81 | ALDH1A1 (0.43) | TDP1LMNAALDH1A1KMT2AMEN1 | |
| SCHEMBL10433026 | 0.80 | ITGB1 (0.39) | ATMTDP1LMNARECQLALDH1A1 | |
| SCHEMBL15271468 | 0.79 | CES2 (0.40) | — | |
| SCHEMBL30289334 | 0.79 | CES2 (0.40) | — | |
| SCHEMBL9031916 | 0.78 | ITGB1 (0.38) | ATMTDP1LMNARECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | claimed |
| CN-112996784-B | Indole derivatives and their use in medicine | 北京越之康泰生物医药科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-109503686-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| US-9963480-B2 | Nucleoside phosphoramidate compound and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2018-05-08 | — | — | US | disclosed |
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD (CN) | 2015-12-17 | — | — | US | disclosed |
| EP-2940031-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-8754240-B2 | Process for the manufacture of 4-fluoro-2-methyl-1H-indol-5-ol | ASTRAZENECA AB (SE) | 2014-06-17 | — | — | US | disclosed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| EP-2540706-A2 | PROCESS FOR PREPARING INDOL-5-OXY-QUINAZOLINE DERIVATIVES AND INTERMEDIATES | AstraZeneca AB (Publ) (SE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012227-A2 | INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0470578-B1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KK (JP) | 1996-11-06 | — | — | EP | disclosed |
| US-5399553-A | Oral absorbability | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1995-03-21 | — | — | US | disclosed |
| US-5254685-A | Tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0470578-A1 | Novel tricyclic compound or salts thereof, method for producing the same and antimicrobial agent containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361123-A1 | NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF | PNP, NUDT1, SLC28A1 | ATM 3947/4885TDP1 2304/4885LMNA 3456/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | ATM 4215/4885TDP1 4766/4885LMNA 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.